X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/01/2855085/33090/en/Axsome-Therapeutics-Initiates-ENGAGE-Phase-3-Trial-of-Solriamfetol-for-the-Treatment-of-Binge-Eating-Disorder.html
https://www.globenewswire.com//news-release/2023/12/07/2792365/33090/en/Axsome-Therapeutics-Hosts-Solriamfetol-Virtual-Investor-Event-with-Expert-Thought-Leaders-Today.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-solriamfetol-hydrochloride-98059.pdf
https://www.globenewswire.com/news-release/2023/07/07/2701004/33090/en/Axsome-Therapeutics-Initiates-FOCUS-Phase-3-Trial-of-Solriamfetol-for-the-Treatment-of-Attention-Deficit-Hyperactivity-Disorder-ADHD-in-Adults.html
https://www.globenewswire.com/news-release/2023/04/21/2651843/33090/en/Axsome-Therapeutics-to-Present-Five-Abstracts-Including-New-Data-from-the-Positive-SHARP-Study-of-SUNOSI-solriamfetol-in-Participants-with-Cognitive-Impairment-with-Excessive-Dayti.html
https://www.globenewswire.com/news-release/2023/02/22/2613017/33090/en/Axsome-Therapeutics-Enters-into-License-Agreement-with-Pharmanovia-to-Expand-Commercialization-and-Further-Develop-Sunosi-solriamfetol-in-Europe.html
https://www.globenewswire.com/news-release/2022/10/03/2526613/33090/en/Axsome-Therapeutics-Announces-Sunosi-Solriamfetol-Meets-Primary-Endpoint-Demonstrating-Improvement-in-Cognitive-Function-in-the-SHARP-Trial-in-Cognitively-Impaired-Patients-with-Ex.html
https://www.prnewswire.com/news-releases/axsome-therapeutics-completes-us-acquisition-of-sunosi-solriamfetol-for-excessive-daytime-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea-301542239.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-completes-us-divestiture-of-sunosi-solriamfetol-to-axsome-therapeutics-301542221.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-agreement-to-divest-sunosi-solriamfetol-to-axsome-therapeutics-301511396.html
https://www.thepharmaletter.com/article/jazz-pharma-partners-with-durbin-on-global-eap-for-narcolepsy-drug#:~:text=Durbin%2C%20part%20of%20Ireland%2Dheadquartered,and%20known%20commercially%20as%20Sunosi.
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-new-data-on-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-and-sunosi-solriamfetol-at-virtual-sleep-2020-301119658.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-receives-eu-marketing-authorisation-for-sunosi-solriamfetol-for-excessive-daytime-sleepiness-in-adults-with-narcolepsy-or-obstructive-sleep-apnea-300989638.html
http://www.koreaherald.com/view.php?ud=20200119000135
https://www.reuters.com/article/us-jazz-phrmt-ema/jazz-pharmas-sleep-disorder-drug-gets-european-panel-backing-idUSKBN1XP1BG
https://www.fiercepharma.com/marketing/jazz-launches-sunosi-week-brand-campaign-to-docs-plus-direct-to-consumer-digital?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/pharma/jazz-plans-early-july-launch-for-sleepiness-med-sunosi-after-dea-scheduling
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-us-fda-approval-of-sunosi-solriamfetol-for-excessive-daytime-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea-300816081.html
https://www.fiercepharma.com/marketing/waiting-green-light-jazz-staffs-up-for-excessive-sleep-treatment-and-vyxeos-push-europe
https://www.biospace.com/article/verily-and-resmed-team-up-on-joint-venture-to-study-sleep-apnea/?s=65
Market Place
Share 
